Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Differences in Cell Cycle Status Underlie Transcriptional Heterogeneity in the HSC Compartment.

Lauridsen FKB, Jensen TL, Rapin N, Aslan D, Wilhelmson AS, Pundhir S, Rehn M, Paul F, Giladi A, Hasemann MS, Serup P, Amit I, Porse BT.

Cell Rep. 2018 Jul 17;24(3):766-780. doi: 10.1016/j.celrep.2018.06.057.

2.

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y.

J Clin Invest. 2018 Oct 1;128(10):4260-4279. doi: 10.1172/JCI97117. Epub 2018 Jul 17.

3.

A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines.

Martin Gonzalez J, Baudet A, Abelechian S, Bonderup K, d'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J.

Genesis. 2018 Sep;56(9):e23238. doi: 10.1002/dvg.23238.

PMID:
30010246
4.

Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin.

Reckzeh K, Kizilkaya H, Helbo AS, Alrich ME, Deslauriers AG, Grover A, Rapin N, Asmar F, Grønbæk K, Porse B, Borregaard N, Vestweber D, Nerlov C, Theilgaard-Mönch K.

Blood Adv. 2018 Jul 10;2(13):1628-1632. doi: 10.1182/bloodadvances.2018015743. No abstract available.

5.

Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null Progenitors.

Pundhir S, Bratt Lauridsen FK, Schuster MB, Jakobsen JS, Ge Y, Schoof EM, Rapin N, Waage J, Hasemann MS, Porse BT.

Cell Rep. 2018 May 29;23(9):2744-2757. doi: 10.1016/j.celrep.2018.05.012.

6.

Testosterone is an endogenous regulator of BAFF and splenic B cell number.

Wilhelmson AS, Lantero Rodriguez M, Stubelius A, Fogelstrand P, Johansson I, Buechler MB, Lianoglou S, Kapoor VN, Johansson ME, Fagman JB, Duhlin A, Tripathi P, Camponeschi A, Porse BT, Rolink AG, Nissbrandt H, Turley SJ, Carlsten H, Mårtensson IL, Karlsson MCI, Tivesten Å.

Nat Commun. 2018 May 25;9(1):2067. doi: 10.1038/s41467-018-04408-0.

7.

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.

Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K.

Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27.

PMID:
28263309
8.

The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery.

Stunnenberg HG; International Human Epigenome Consortium, Hirst M.

Cell. 2016 Nov 17;167(5):1145-1149. doi: 10.1016/j.cell.2016.11.007. Erratum in: Cell. 2016 Dec 15;167(7):1897.

9.

UPF2-Dependent Nonsense-Mediated mRNA Decay Pathway Is Essential for Spermatogenesis by Selectively Eliminating Longer 3'UTR Transcripts.

Bao J, Vitting-Seerup K, Waage J, Tang C, Ge Y, Porse BT, Yan W.

PLoS Genet. 2016 May 5;12(5):e1005863. doi: 10.1371/journal.pgen.1005863. eCollection 2016 May.

10.

Peak-valley-peak pattern of histone modifications delineates active regulatory elements and their directionality.

Pundhir S, Bagger FO, Lauridsen FB, Rapin N, Porse BT.

Nucleic Acids Res. 2016 May 19;44(9):4037-51. doi: 10.1093/nar/gkw250. Epub 2016 Apr 19.

11.

The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

O'Connor C, Lohan F, Campos J, Ohlsson E, Salomè M, Forde C, Artschwager R, Liskamp RM, Cahill MR, Kiely PA, Porse B, Keeshan K.

Oncogene. 2016 Oct 6;35(40):5272-5281. doi: 10.1038/onc.2016.66. Epub 2016 Mar 21.

PMID:
26996668
12.

C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4.

Di Stefano B, Collombet S, Jakobsen JS, Wierer M, Sardina JL, Lackner A, Stadhouders R, Segura-Morales C, Francesconi M, Limone F, Mann M, Porse B, Thieffry D, Graf T.

Nat Cell Biol. 2016 Apr;18(4):371-81. doi: 10.1038/ncb3326. Epub 2016 Mar 14.

PMID:
26974661
13.

Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors.

Paul F, Arkin Y, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, Winter D, Lara-Astiaso D, Gury M, Weiner A, David E, Cohen N, Lauridsen FKB, Haas S, Schlitzer A, Mildner A, Ginhoux F, Jung S, Trumpp A, Porse BT, Tanay A, Amit I.

Cell. 2016 Jan 14;164(1-2):325. doi: 10.1016/j.cell.2015.12.046. Epub 2016 Jan 14. No abstract available.

14.

Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors.

Paul F, Arkin Y, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, Winter D, Lara-Astiaso D, Gury M, Weiner A, David E, Cohen N, Lauridsen FK, Haas S, Schlitzer A, Mildner A, Ginhoux F, Jung S, Trumpp A, Porse BT, Tanay A, Amit I.

Cell. 2015 Dec 17;163(7):1663-77. doi: 10.1016/j.cell.2015.11.013. Epub 2015 Nov 25. Erratum in: Cell. 2016 Jan 14;164(1-2):325.

15.

The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.

Ohlsson E, Schuster MB, Hasemann M, Porse BT.

Leukemia. 2016 Apr;30(4):767-75. doi: 10.1038/leu.2015.324. Epub 2015 Nov 25. Review.

PMID:
26601784
16.

BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis.

Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sønderby CK, Winther O, Rapin N, Porse BT.

Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24. doi: 10.1093/nar/gkv1101. Epub 2015 Oct 26.

17.

ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiation.

Knudsen KJ, Rehn M, Hasemann MS, Rapin N, Bagger FO, Ohlsson E, Willer A, Frank AK, Søndergaard E, Jendholm J, Thorén L, Lee J, Rak J, Theilgaard-Mönch K, Porse BT.

Genes Dev. 2015 Sep 15;29(18):1915-29. doi: 10.1101/gad.268409.115.

18.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J.

Blood. 2015 Sep 3;126(10):1214-23. doi: 10.1182/blood-2015-05-647172. Epub 2015 Jul 10.

19.

Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.

Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K.

Genes Dev. 2015 May 1;29(9):910-22. doi: 10.1101/gad.260174.115. Epub 2015 Apr 17.

20.

Cellular origin of prognostic chromosomal aberrations in AML patients.

Mora-Jensen H, Jendholm J, Rapin N, Andersen MK, Roug AS, Bagger FO, Bullinger L, Winther O, Borregaard N, Porse BT, Theilgaard-Mönch K.

Leukemia. 2015 Aug;29(8):1785-9. doi: 10.1038/leu.2015.30. Epub 2015 Feb 11. No abstract available.

PMID:
25670329

Supplemental Content

Loading ...
Support Center